ArticleJAMA network open2026
Periprocedural Mortality Risk After Elective Atrial Fibrillation Ablation in Japan.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Errors in Funding/Support Statement and Conflict of Interest Disclosures.JAMA network open · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Evidence on the safety of atrial fibrillation ablation during rapid growth in both procedural volume and the number of hospitals performing it remains inconsistent. Although clinical registries and randomized trial meta-analyses report extremely low mortality, administrative databases have suggested rates up to 10-fold higher, with concerning temporal increases. Objective: To define the periprocedural mortality risk following elective atrial fibrillation ablation using a validated nationwide database and to determine whether this expansion was associated with diffusion-related safety penalties (ie, transient erosion of safety driven by a widening efficacy-effectiveness gap). Design, Setting, and Participants: This retrospective, nationwide, population-based cohort study used data from a nationwide administrative database of participating cardiovascular hospitals in Japan from April 1, 2012, to March 31, 2023. Analyses were conducted in 2025 to 2026, with follow-up through discharge from the index hospitalization for the primary outcome. Patients with atrial fibrillation who underwent scheduled elective catheter ablation with transseptal puncture were included. Exposures: Elective atrial fibrillation ablation. Main Outcomes and Measures: The primary outcome was in-hospital mortality during the index hospitalization. In-hospital mortality and other event rates are presented as proportions with exact (Clopper-Pearson) binomial 95% CIs. Multivariable analyses used Firth penalized logistic regression. Results: Among 618 024 catheter ablation procedures, 412 947 were elective atrial fibrillation ablations (median [IQR] patient age, 68 [60-74] years; 288 825 male patients [69.9%]) performed between 2012 and 2022. Annual procedural volume increased from 10 969 procedures in 2012 to 63 014 procedures in 2022. In-hospital mortality occurred in 119 patients (0.029%; 95% CI, 0.024%-0.034%), with a modest but statistically significant decline (P for trend = .04). Within 30 days of the procedure, deaths occurred during the index hospitalization in 91 patients (0.022%; 95% CI, 0.018%-0.027%) and during readmission in 72 patients (0.017%; 95% CI, 0.014%-0.022%). The most frequent concurrent complication among index-hospitalization deaths was cardiac tamponade (26 patients [21.8%]). In Firth penalized multivariable analysis, factors independently associated with in-hospital mortality included older age (odds ratio [OR], 1.04; 95% CI, 1.01-1.07), lower body mass index (OR, 0.94; 95% CI, 0.89-1.00), Charlson Comorbidity Index score of 3 or higher (OR, 4.59; 95% CI, 2.59-8.12), low institutional volume (OR, 2.52; 95% CI, 1.45-4.38), and preserved functional status (Barthel Index >90; OR, 0.11; 95% CI, 0.07-0.19). Conclusions and Relevance: In this Japanese nationwide registry study of 412 947 elective atrial fibrillation ablation procedures, in-hospital mortality was 0.029%, comparable to contemporary registry benchmarks. No evidence of a diffusion-related safety penalty was observed during rapid expansion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.